Study of the Impact of Non-pharmacological Techniques on Cognitive Complaints in Cancer Patients
NCT05943301, Not applicable, Withdrawn, University of Liege
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Study of the Impact of Non-pharmacological Techniques on Cognitive Complaints in Cancer Patients | ClinicalTrials.gov |
| NCT number | NCT05943301 | ClinicalTrials.gov |
| Status | Withdrawn | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 0 participants, actual | ClinicalTrials.gov |
| Lead sponsor | University of Liege | ClinicalTrials.gov |
| Conditions | Non-Metastatic Neoplasm | ClinicalTrials.gov |
| Interventions | Self-hypnosis/self-care | ClinicalTrials.gov |
| First posted | 2023-07-13 | ClinicalTrials.gov |
| Last updated | 2023-07-13 | ClinicalTrials.gov |
Registered outcomes 21
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Change in subjective cognitive difficulties : Perceived cognitive impairments | T1 (before the intervention), T2 (right after the intervention), T3 (3 months follow-up) | The impact of self-hypnosis/self-care on the perceived cognitive impairments will be assessed by means of the subtest "Perceived cognitive impairments" of the Functionnal Assessment of Cancer Therapy-Cognitive Function (FACT-COG; Wagner et al., 2009). Scale ranging from 0 to 4 (0=never; 4=several times a day). | ClinicalTrials.gov |
| Primary | Change in subjective cognitive difficulties : Comments by others | T1 (before the intervention), T2 (right after the intervention), T3 (3 months follow-up) | The impact of self-hypnosis/self-care on the perceived cognitive impairments will be assessed by means of the subtest "Comments by others" of the Functionnal Assessment of Cancer Therapy-Cognitive Function (FACT-COG; Wagner et al., 2009). Scale ranging from 0 to 4 (0=never; 4=several times a day). | ClinicalTrials.gov |
| Primary | Change in subjective cognitive difficulties : Perceived cognitive abilities | T1 (before the intervention), T2 (right after the intervention), T3 (3 months follow-up) | The impact of self-hypnosis/self-care on the perceived cognitive impairments will be assessed by means of the subtest "Perceived cognitive abilities" of the Functionnal Assessment of Cancer Therapy-Cognitive Function (FACT-COG; Wagner et al., 2009). Scale ranging from 0 to 4 (0=not at all; 4=very much). | ClinicalTrials.gov |
| Primary | Change in subjective cognitive difficulties : Impact on quality of life | T1 (before the intervention), T2 (right after the intervention), T3 (3 months follow-up) | The impact of self-hypnosis/self-care on the perceived cognitive impairments will be assessed by means of the subtest "Impact on quality of life" of the Functionnal Assessment of Cancer Therapy-Cognitive Function (FACT-COG; Wagner et al., 2009). Scale ranging from 0 to 4 (0=not at all; 4=very much). | ClinicalTrials.gov |
| Primary | Change in objective cognitive difficulties : Verbal long term memory | T1 (before the intervention), T2 (right after the intervention), T3 (3 months follow-up) | The impact of self-hypnosis/self-care on verbal long term memory will be assessed by means the Buschke Selective Reminding Test (Buschke, 1973). According to the sex and the subject's age, the test gives us a score and the norms. | ClinicalTrials.gov |
| Primary | Change in objective cognitive difficulties : Attention | T1 (before the intervention), T2 (right after the intervention), T3 (3 months follow-up) | The impact of self-hypnosis/self-care on attention abilities will be assessed by means of the subtest "Phasic alertness" of the Test of Attentional Performance 2.3.1 (Zimmermann \& Fimm, 2002). Computerized test, according to the sex and the subject's age, the test gives us a score and the norms. | ClinicalTrials.gov |
| Primary | Change in objective cognitive difficulties : Processing speed | T1 (before the intervention), T2 (right after the intervention), T3 (3 months follow-up) | The impact of self-hypnosis/self-care on processing speed abilities will be assessed by means of the first part of the Stroop test (Stroop, 1935). According to the sex and the subject's age, the test gives us a score and the norms. | ClinicalTrials.gov |
| Primary | Change in objective cognitvie difficulties : Inhibition | T1 (before the intervention), T2 (right after the intervention), T3 (3 months follow-up) | The impact of self-hypnosis/self-care on inhibition abilities will be assessed by means of the first part of the Stroop test (Stroop, 1935). According to the sex and the subject's age, the test gives us a score and the norms. | ClinicalTrials.gov |
| Primary | Change in objective cognitvie difficulties : mental flexibility | T1 (before the intervention), T2 (right after the intervention), T3 (3 months follow-up) | The impact of self-hypnosis/self-care on mental flexibility abilities will be assessed by means of the subtest "Flexibility" of the Test of Attentional Performance 2.3.1 (Zimmermann \& Fimm, 2002). Computerized test, according to the sex and the subject's age, the test gives us a score and the norms. | ClinicalTrials.gov |
| Primary | Change in objective cognitvie difficulties : working memory | T1 (before the intervention), T2 (right after the intervention), T3 (3 months follow-up) | The impact of self-hypnosis/self-care on mental flexibility abilities will be assessed by means of the subtest "Working memory" of the Test of Attentional Performance 2.3.1 (Zimmermann \& Fimm, 2002). Computerized test, according to the sex and the subject's age, the test gives us a score and the norms. | ClinicalTrials.gov |
| Primary | Change in objective cognitvie difficulties : executive functions | T1 (before the intervention), T2 (right after the intervention), T3 (3 months follow-up) | The impact of self-hypnosis/self-care on executive functions will be assessed by means of the Wisconsin Card Sorting Test (David et al., 1948). According to the sex and the subject's age, the test gives us a score and the norms. | ClinicalTrials.gov |
| Primary | Impact on return-to-work | T1 (before the intervention), T2 (right after the intervention), T3 (3 months follow-up) | For people who continued to work at time of recruitment, Work Design questionnaire will be administered Morgeson \& Hymphrey, 2006). Scale raging from 0 to 5 (0=not at all; 5=exactly). | ClinicalTrials.gov |
| Secondary | Change in emtional distress : Anxiety | T1 (before the intervention), T2 (right after the intervention), T3 (3 months follow-up) | The impact of self-hypnosis/self-care on anxiety and despression will be assessed by means of the Hopsital Anxiety and Depression Scale (Zigmond \& Snaith, 1983). Scale ranging from 0 to 3 (0=never; 4=always). | ClinicalTrials.gov |
| Secondary | Change in emtional distress : Depression | T1 (before the intervention), T2 (right after the intervention), T3 (3 months follow-up) | The impact of self-hypnosis/self-care on anxiety and despression will be assessed by means of the Hopsital Anxiety and Depression Scale (Zigmond \& Snaith, 1983). Scale ranging from 0 to 3 (0=alwaysr; 4=never). | ClinicalTrials.gov |
| Secondary | Change in fatigue : General fatigue | T1 (before the intervention), T2 (right after the intervention), T3 (3 months follow-up) | The impact of self-hypnosis/self-care on fatigue will be assessed by means of the subscale "general fatigue" of the Multidimensional Fatigue Inventory (Smets et al., 1995). Scale ranging from 1 to 4 (1=not agree at all; 4=agree completely). | ClinicalTrials.gov |
| Secondary | Change in fatigue : Physical fatigue | T1 (before the intervention), T2 (right after the intervention), T3 (3 months follow-up) | The impact of self-hypnosis/self-care on fatigue will be assessed by means of the subscale "physical fatigue" of the Multidimensional Fatigue Inventory (Smets et al., 1995). Scale ranging from 1 to 4 (1=not agree at all; 4=agree completely). | ClinicalTrials.gov |
| Secondary | Change in fatigue : Mental fatigue | T1 (before the intervention), T2 (right after the intervention), T3 (3 months follow-up) | The impact of self-hypnosis/self-care on fatigue will be assessed by means of the subscale "mental fatigue" of the Multidimensional Fatigue Inventory (Smets et al., 1995). Scale ranging from 1 to 4 (1=not agree at all; 4=agree completely). | ClinicalTrials.gov |
| Secondary | Change in fatigue : Motivational decrease | T1 (before the intervention), T2 (right after the intervention), T3 (3 months follow-up) | The impact of self-hypnosis/self-care on fatigue will be assessed by means of the subscale "motivational decrease" of the Multidimensional Fatigue Inventory (Smets et al., 1995). Scale ranging from 1 to 4 (1=not agree at all; 4=agree completely). | ClinicalTrials.gov |
| Secondary | Change in fatigue | T1 (before the intervention), T2 (right after the intervention), T3 (3 months follow-up) | The impact of self-hypnosis/self-care on fatigue will be assessed by means of the Multidimensional Fatigue Inventory (MFI; Smets et al., 1995) and an 1-week agenda. | ClinicalTrials.gov |
| Secondary | Change in fatigue : Weekly agenda | T1 (before the intervention), T2 (right after the intervention), T3 (3 months follow-up) | Qualitative questionnaire concerning the sleep habits of participants. They have to give information concerning their sleeping habits. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 3
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Card Sorting Test (Berg) | Primary outcome | ConductCognition |
| Selective Reminding Task | Primary outcome | ConductCognition |
| Stroop Color-Word Test | Primary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)